AssetMark Inc’s Tonix Pharmaceuticals TNXP Stock Holding History

AssetMark Inc’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38	Hold	3	–	–	﹤0.01%	3512
2026 Q1	$41	Hold	3	–	–	﹤0.01%	3406
2025 Q4	$47	Hold	3	–	–	﹤0.01%	3338
2025 Q3	$72	Hold	3	–	–	﹤0.01%	3138
2025 Q2	$108	Hold	3	–	–	﹤0.01%	2934
2025 Q1	$54	Buy	+3	New	+$61	﹤0.01%	2591

Other funds holding TNXP

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

SIC

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CNBT

Cornerstone National Bank & Trust Palatine, Illinois $296M AUM 12.13% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SOW

State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AssetMark Inc's TNXP Position: Q2 2026 in Review

AssetMark Inc held its Tonix Pharmaceuticals (TNXP) position steady in Q2 2026 at 3 shares worth $38. The position accounts for ﹤0.01% of the portfolio, ranked #3512.

AssetMark Inc first reported a position in TNXP in Q1 2025 and has held it in 6 quarters since. The position peaked at $108 in Q2 2025. 24 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

AssetMark Inc held 3 shares of Tonix Pharmaceuticals worth $38 as of Q2 2026.
AssetMark Inc left its Tonix Pharmaceuticals share count unchanged in Q2 2026.
Tonix Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3512 holding.
AssetMark Inc first reported a position in Tonix Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
AssetMark Inc's Tonix Pharmaceuticals position peaked at $108 in Q2 2025.
24 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.